{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T16:46:38Z","timestamp":1751561198872},"reference-count":27,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2019.10909","type":"journal-article","created":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T07:32:21Z","timestamp":1569223941000},"source":"Crossref","is-referenced-by-count":4,"title":["Different responses to anti\u2011programmed cell death protein 1 (PD\u20111) immunotherapy in a patient with Lynch syndrome and metachronous urothelial and colon cancer: A case report"],"prefix":"10.3892","author":[{"given":"Yu","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufeng","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250001, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingming","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of R&D, Geneplus\u2011Beijing Institute, Beijing 102206, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongrong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of R&D, Geneplus\u2011Beijing Institute, Beijing 102206, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingsheng","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2019,9,23]]},"reference":[{"key":"key20200714091943_b1-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrc3878","article-title":"Milestones of Lynch syndrome: 1895\u20132015","volume":"15","author":"Lynch","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"key20200714091943_b2-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"key20200714091943_b3-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"key20200714091943_b4-ol-0-0-10909","author":"Food and Drug Administration (FDA)","year":"2018"},{"key":"key20200714091943_b5-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1245\/s10434-012-2858-5","article-title":"Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers","volume":"20","author":"Win","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"key20200714091943_b6-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1002\/ijc.25501","article-title":"Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma","volume":"127","author":"Obermair","year":"2010","journal-title":"Int J Cancer"},{"key":"key20200714091943_b7-ol-0-0-10909","article-title":"Pathology and genetics of tumours of the urinary system and male genital organs: WHO classification of tumours","author":"Eble","year":"2004","journal-title":"World Health Organ"},{"key":"key20200714091943_b8-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1136\/ijgc-00009577-200605000-00072","article-title":"MSH2 splice site mutation and endometrial cancer","volume":"16","author":"Bianchi","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"key20200714091943_b9-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cancergen.2019.08.002","article-title":"Confirmation of damaging effect of MSH2 c. 2634+ 1G>C mutation on splicing, its classification and implications for counseling","volume":"239","author":"Rakobradovi\u0107","year":"2019","journal-title":"Cancer Genet"},{"key":"key20200714091943_b10-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"key20200714091943_b11-ol-0-0-10909","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0273","article-title":"Giant bilateral adrenal myelolipomas in two Chinese families with congenital adrenal hyperplasia","author":"Liu","year":"2018","journal-title":"Endocr Connect"},{"key":"key20200714091943_b12-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20200714091943_b13-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1001\/jama.2011.743","article-title":"Cancer risks associated with germline mutations in MLH1, MSH2 and MSH6 genes in Lynch syndrome","volume":"305","author":"Bonadona","year":"2011","journal-title":"JAMA"},{"key":"key20200714091943_b14-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/gutjnl-2015-309675","article-title":"Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: First report from the prospective Lynch syndrome database","volume":"66","author":"M\u00f8ller","year":"2017","journal-title":"Gut"},{"key":"key20200714091943_b15-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1136\/gutjnl-2017-314057","article-title":"Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: A report from the Prospective Lynch Syndrome Database","volume":"67","author":"M\u00f8ller","year":"2018","journal-title":"Gut"},{"key":"key20200714091943_b16-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3109\/00365521.2012.752030","article-title":"Hepatocellular carcinoma as extracolonic manifestation of Lynch syndrome indicates SEC63 as potential target gene in hepatocarcinogenesis","volume":"48","author":"Casper","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"key20200714091943_b17-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10689-006-9105-9","article-title":"A case of Muir-Torre syndrome associated with mucinous hepatic cholangiocarcinoma and a novel germline mutation of the MSH2 gene","volume":"6","author":"Vernez","year":"2007","journal-title":"Fam Cancer"},{"key":"key20200714091943_b18-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/j.1399-0004.2007.00911.x","article-title":"Germline hMSH2 promoter mutation in a Chinese HNPCC kindred: Evidence for dual role of LOH","volume":"72","author":"Yan","year":"2007","journal-title":"Clin Genet"},{"key":"key20200714091943_b19-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/ng1294-405","article-title":"Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer","volume":"8","author":"Hemminki","year":"1994","journal-title":"Nat Genet"},{"key":"key20200714091943_b20-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"key20200714091943_b21-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.intimp.2018.03.018","article-title":"Pseudoprogression and hyperprogression after checkpoint blockade","volume":"58","author":"Wang","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"key20200714091943_b22-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1053\/j.seminoncol.2015.10.001","article-title":"Practical approaches to immunotherapy in the clinic","volume":"42","author":"Agarwala","year":"2015","journal-title":"Semin Oncol"},{"key":"key20200714091943_b23-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"38056","DOI":"10.18632\/oncotarget.16935","article-title":"Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma","volume":"8","author":"Guibert","year":"2017","journal-title":"Oncotarget"},{"key":"key20200714091943_b24-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jamaoncol.2017.5332","article-title":"Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies","volume":"4","author":"Lee","year":"2018","journal-title":"JAMA Oncol"},{"key":"key20200714091943_b25-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"key20200714091943_b26-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced Urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"key20200714091943_b27-ol-0-0-10909","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/cam4.1372","article-title":"Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients","volume":"7","author":"Vanderwalde","year":"2018","journal-title":"Cancer Med"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T09:57:28Z","timestamp":1594720648000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2019.10909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,23]]},"references-count":27,"URL":"https:\/\/doi.org\/10.3892\/ol.2019.10909","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,23]]}}}